Amgen’s blood cancer drug gets full EU licence
FDA granted full licence last year
X
Amgen’s blood cancer drug gets full EU licence
https://pharmaphorum.com/news/amgens-blood-cancer-drug-blincyto-licence/
acute lymphoblastic leukaemia
NICE to reassess Pfizer blood cancer drug
Company successfully appealed against rejection last summer
Novartis close to first-ever CAR-T approval after unanimous vote
Panel unanimously back CTL019
Pfizer facing NICE showdown over leukaemia drug
Pfizer locks horns with NICE following EU approval.
NICE backs Amgen’s Blincyto in rare leukaemia
Drug will also be available to children via Cancer Drugs Fund.
